Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)

Autores
Cutini, Pablo Hernan; Massheimer, Virginia Laura
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
In atherosclerosis, the generation of microvessels within the plaques represents a survival option for damaged tissue but would also be associated with the instability of the plaque. The risk/benefit of hormone replacement therapy using natural or synthetic progestins such MPA as an alternative to prevent cardiovascular diseases in menopausal women is controversial. The aim of this work was to evaluate the mechanism of action by which Pg and MPA regulate angiogenesis. Tube formation assay and endothelial cell (EC) culture derived from murine aorta were used to evaluate angiogenesis. Total tube length of vessel segments was quantified using ImageJ software. Both progestogens significantly enhanced the number of tube structures (26%; 46% above control, 100 nM Pg; 100 nM MPA respectively, p<0.05). Firstlywe tested the participation of Pg receptor (PgR). Pre-treatment of EC with RU486, an antagonist of PgR, completely inhibited the proangiogenic effect of Pg and MPA. Considering that VEGF is the main regulator of angiogenesis, we neutralize its action with a VEGF antibody (a-VEGF). Besides, we used the compound genistein to block the tyrosine kinase activity of VEGF receptor (VEGFR). The presence of a-VEGF or genistein abrogates the proangiogenic action of Pg. Meanwhile, the effect of MPA was not modified. Nitric oxide synthase (NOS) is involved in VEGFR downstream signaling pathway. In the presence of L-NAME, a NOS inhibitor, the stimulation of tube formation induced by Pg was blunted. Meanwhile, MPA action was not affected. The proangiogenic action of Pg was not altered by the presence of platelet-rich-plasma (PRP)-derived plasma. Instead, the MPA action was potentiated (29% vs 100 nM MPA, p<0.05). We demonstrated that 100 nM Pg markedly increased VEGF synthesis (39% vs control, p<0.05). In contrast, MPA (100 nM) did not affect VEGF production. In conclusion, both progestogens promote angiogenesis with a slight different mechanism of action elicited by each steroid.
Fil: Cutini, Pablo Hernan. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Massheimer, Virginia Laura. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de Nanomedicinas
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Biología
Asociación Argentina de Farmacología Experimenta
Asociación Argentina de Nanomedicinas
Sociedad Argentina de Protozoología
Materia
ANGIOGENESIS
VASCULAR REMODELING
PROGESTERONE
MEDROXY PROGESTERONE ACETATE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/191311
Acceder
id CONICETDig_4aeef21df6420b168cfc46be1cb3d854
oai_identifier_str oai:ri.conicet.gov.ar:11336/191311
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)Cutini, Pablo HernanMassheimer, Virginia LauraANGIOGENESISVASCULAR REMODELINGPROGESTERONEMEDROXY PROGESTERONE ACETATEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3In atherosclerosis, the generation of microvessels within the plaques represents a survival option for damaged tissue but would also be associated with the instability of the plaque. The risk/benefit of hormone replacement therapy using natural or synthetic progestins such MPA as an alternative to prevent cardiovascular diseases in menopausal women is controversial. The aim of this work was to evaluate the mechanism of action by which Pg and MPA regulate angiogenesis. Tube formation assay and endothelial cell (EC) culture derived from murine aorta were used to evaluate angiogenesis. Total tube length of vessel segments was quantified using ImageJ software. Both progestogens significantly enhanced the number of tube structures (26%; 46% above control, 100 nM Pg; 100 nM MPA respectively, p<0.05). Firstlywe tested the participation of Pg receptor (PgR). Pre-treatment of EC with RU486, an antagonist of PgR, completely inhibited the proangiogenic effect of Pg and MPA. Considering that VEGF is the main regulator of angiogenesis, we neutralize its action with a VEGF antibody (a-VEGF). Besides, we used the compound genistein to block the tyrosine kinase activity of VEGF receptor (VEGFR). The presence of a-VEGF or genistein abrogates the proangiogenic action of Pg. Meanwhile, the effect of MPA was not modified. Nitric oxide synthase (NOS) is involved in VEGFR downstream signaling pathway. In the presence of L-NAME, a NOS inhibitor, the stimulation of tube formation induced by Pg was blunted. Meanwhile, MPA action was not affected. The proangiogenic action of Pg was not altered by the presence of platelet-rich-plasma (PRP)-derived plasma. Instead, the MPA action was potentiated (29% vs 100 nM MPA, p<0.05). We demonstrated that 100 nM Pg markedly increased VEGF synthesis (39% vs control, p<0.05). In contrast, MPA (100 nM) did not affect VEGF production. In conclusion, both progestogens promote angiogenesis with a slight different mechanism of action elicited by each steroid.Fil: Cutini, Pablo Hernan. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaFil: Massheimer, Virginia Laura. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaLXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de NanomedicinasMar del PlataArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de BiologíaAsociación Argentina de Farmacología ExperimentaAsociación Argentina de NanomedicinasSociedad Argentina de ProtozoologíaFundación Revista MedicinaAzurmendi, Pablo Javier2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/191311Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA); LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de Nanomedicinas ; Mar del Plata; Argentina; 2019; 67-671669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.cominfo:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:56Zoai:ri.conicet.gov.ar:11336/191311instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:57.618CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
title Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
spellingShingle Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
Cutini, Pablo Hernan
ANGIOGENESIS
VASCULAR REMODELING
PROGESTERONE
MEDROXY PROGESTERONE ACETATE
title_short Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
title_full Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
title_fullStr Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
title_full_unstemmed Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
title_sort Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA)
dc.creator.none.fl_str_mv Cutini, Pablo Hernan
Massheimer, Virginia Laura
author Cutini, Pablo Hernan
author_facet Cutini, Pablo Hernan
Massheimer, Virginia Laura
author_role author
author2 Massheimer, Virginia Laura
author2_role author
dc.contributor.none.fl_str_mv Azurmendi, Pablo Javier
dc.subject.none.fl_str_mv ANGIOGENESIS
VASCULAR REMODELING
PROGESTERONE
MEDROXY PROGESTERONE ACETATE
topic ANGIOGENESIS
VASCULAR REMODELING
PROGESTERONE
MEDROXY PROGESTERONE ACETATE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In atherosclerosis, the generation of microvessels within the plaques represents a survival option for damaged tissue but would also be associated with the instability of the plaque. The risk/benefit of hormone replacement therapy using natural or synthetic progestins such MPA as an alternative to prevent cardiovascular diseases in menopausal women is controversial. The aim of this work was to evaluate the mechanism of action by which Pg and MPA regulate angiogenesis. Tube formation assay and endothelial cell (EC) culture derived from murine aorta were used to evaluate angiogenesis. Total tube length of vessel segments was quantified using ImageJ software. Both progestogens significantly enhanced the number of tube structures (26%; 46% above control, 100 nM Pg; 100 nM MPA respectively, p<0.05). Firstlywe tested the participation of Pg receptor (PgR). Pre-treatment of EC with RU486, an antagonist of PgR, completely inhibited the proangiogenic effect of Pg and MPA. Considering that VEGF is the main regulator of angiogenesis, we neutralize its action with a VEGF antibody (a-VEGF). Besides, we used the compound genistein to block the tyrosine kinase activity of VEGF receptor (VEGFR). The presence of a-VEGF or genistein abrogates the proangiogenic action of Pg. Meanwhile, the effect of MPA was not modified. Nitric oxide synthase (NOS) is involved in VEGFR downstream signaling pathway. In the presence of L-NAME, a NOS inhibitor, the stimulation of tube formation induced by Pg was blunted. Meanwhile, MPA action was not affected. The proangiogenic action of Pg was not altered by the presence of platelet-rich-plasma (PRP)-derived plasma. Instead, the MPA action was potentiated (29% vs 100 nM MPA, p<0.05). We demonstrated that 100 nM Pg markedly increased VEGF synthesis (39% vs control, p<0.05). In contrast, MPA (100 nM) did not affect VEGF production. In conclusion, both progestogens promote angiogenesis with a slight different mechanism of action elicited by each steroid.
Fil: Cutini, Pablo Hernan. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Massheimer, Virginia Laura. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Cátedra de Bioquímica Clinica Ii; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de Nanomedicinas
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Biología
Asociación Argentina de Farmacología Experimenta
Asociación Argentina de Nanomedicinas
Sociedad Argentina de Protozoología
description In atherosclerosis, the generation of microvessels within the plaques represents a survival option for damaged tissue but would also be associated with the instability of the plaque. The risk/benefit of hormone replacement therapy using natural or synthetic progestins such MPA as an alternative to prevent cardiovascular diseases in menopausal women is controversial. The aim of this work was to evaluate the mechanism of action by which Pg and MPA regulate angiogenesis. Tube formation assay and endothelial cell (EC) culture derived from murine aorta were used to evaluate angiogenesis. Total tube length of vessel segments was quantified using ImageJ software. Both progestogens significantly enhanced the number of tube structures (26%; 46% above control, 100 nM Pg; 100 nM MPA respectively, p<0.05). Firstlywe tested the participation of Pg receptor (PgR). Pre-treatment of EC with RU486, an antagonist of PgR, completely inhibited the proangiogenic effect of Pg and MPA. Considering that VEGF is the main regulator of angiogenesis, we neutralize its action with a VEGF antibody (a-VEGF). Besides, we used the compound genistein to block the tyrosine kinase activity of VEGF receptor (VEGFR). The presence of a-VEGF or genistein abrogates the proangiogenic action of Pg. Meanwhile, the effect of MPA was not modified. Nitric oxide synthase (NOS) is involved in VEGFR downstream signaling pathway. In the presence of L-NAME, a NOS inhibitor, the stimulation of tube formation induced by Pg was blunted. Meanwhile, MPA action was not affected. The proangiogenic action of Pg was not altered by the presence of platelet-rich-plasma (PRP)-derived plasma. Instead, the MPA action was potentiated (29% vs 100 nM MPA, p<0.05). We demonstrated that 100 nM Pg markedly increased VEGF synthesis (39% vs control, p<0.05). In contrast, MPA (100 nM) did not affect VEGF production. In conclusion, both progestogens promote angiogenesis with a slight different mechanism of action elicited by each steroid.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/191311
Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA); LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de Nanomedicinas ; Mar del Plata; Argentina; 2019; 67-67
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/191311
identifier_str_mv Angiogenesis regulation: different mechanism of action elicited by progesterone (Pg) and medroxyprogesterone acetate (MPA); LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología y IX Reunión Anual de la Asociación Argentina de Nanomedicinas ; Mar del Plata; Argentina; 2019; 67-67
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com
info:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269313711472640
score 13.13397

Publicaciones similares